Bullous systemic lupus erythematosus (BSLE) is a rare bullous dermatosis in patients with systemic lupus erythematosus. It is characterized by clinical and histologic features, resembling either bullous pemphigoid or dermatitis…
Epidermolysis bullosa acquisita is a rare and debilitating autoimmune mucocutaneous blistering disease caused by autoantibodies directed against type VII collagen or anchoring fibrils in the subepidermal basement membrane zone. Treatment…
The therapeutic approach to mucous membrane pemphigoid is site specific, with the goal of preserving function for patients with chronic and treatment-resistant disease. The involvement of certain mucosal sites (ie,…
The major treatment strategies for DH are gluten restriction or medical treatment with sulfones. Control of the cutaneous manifestations, but not the gastrointestinal changes, is rapid with dapsone. In addition…
Linear immunoglobulin A (IgA) disease is an acquired autoimmune blistering disease of the skin and mucous membranes that runs a chronic course over 3 to 6 years before remitting. It…
Pemphigoid gestationis is an autoimmune blistering disease of pregnancy caused by autoantibodies directed against BP180 (type XVII collagen) in the basement membrane zone. This article discusses the current management of…
Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease typically affecting the elderly. Although different therapeutic regimens have been proposed, a review of the evidence is needed to…
Paraneoplastic pemphigus (PNP) or paraneoplastic autoimmune multiorgan syndrome (PAMS) is a life-threatening autoimmune blistering disease commonly associated with lymphoproliferative neoplasms. This article focuses on current management strategies in PNP/PAMS, and…
Infection contributes to considerable morbidity and mortality in patients treated for autoimmune bullous disorders because of the impaired cutaneous barrier, alteration of the protective normal flora, and host immunosuppression (inherent…
Treatment modalities in pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are many and varied, although level 1 evidence supporting their use is limited. To date, only 2 systematic reviews exist…
